NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adjuvance Technologies

Adjuvance Technologies

Private
Lincoln, NebraskaHealthcare & Life Scienceshttps://adjuvancetechnologies.com

Last Round

Series A

May 27, 2020

Total Funding Raised

$47.86M

Company Overview

Adjuvance Technologies is a biopharmaceutical company that develops and manufactures proprietary saponin-based vaccine adjuvants to improve immune responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

vaccine adjuvantsaponin-based adjuvantbiotechnologyvaccine developmentdrug discoverysynthetic adjuvantbiotech R&Dclinical developmentimmunologybiopharmavaccine techIP licensingTQL1055

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adjuvance Technologies Comparables

Compare Adjuvance Technologies with similar companies based on industry and business-model similarity.

Adjuvance Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Q-Vant Biosciences
85%
TollereBio
82%
Inimmune
79%

Adjuvance Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 27, 2020
GrantMay 19, 2020
Series AJan 30, 2020
GrantSep 1, 2017
SeedNov 14, 2016
Grant
Jun 6, 2014

Adjuvance Technologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2020

    $1.47M grant from National Institute of Allergy and Infectious Diseases

  • Jun 6, 2014

    $1.7M grant received from NIH RADx

Adjuvance Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adjuvance Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adjuvance Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersLincoln, Nebraska
Year Founded2009
Last FundingMay 27, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.